http://ift.tt/eA8V8J
SHANGHAI–(BUSINESS WIRE)–EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today announced the completion of a $25 million Series A financing round. The financing was led by Oriza Seed Capital and included investments from Decheng Capital, 3E Bioventures Capital and the Trend Investment Group. With the funding, Epimab will advance its proprietary bispecific platform technology and build a pipeline of therapeutic candidates in i
April 25, 2017 at 10:14AM
from
No comments:
Post a Comment